Table 2.

Increase in eNPV per investigational drug for phase II decentralized clinical trials (thousands 2020 USD): variation in combination of screen failure, amendments and cycle time effects

Factor effects	eNPV delta	eNPV delta as percent of base eNPV (%)	ROI
Amendments only	− $1014	− 0.3	-0.54x
Screen failure only	− $148	< − 0.1	-0.08x
Cycle time only	$7121	2.3	3.76x
Screen failure plus amendments	$224	< 0.1	0.12x
Amendments plus cycle time	$7497	2.4	3.96x
Screen failure plus cycle time	$8374	2.7	4.43x

Costs and returns discounted to the start of phase II testing

ROI eNPV delta/Implementation cost